HomeLegal DirectoryFDA PCCP Guidance (AI/ML devices)

In effect Moderate protection

FDA Final Guidance — Predetermined Change Control Plans for AI/ML-Enabled Device Software Functions

United States · FDA Guidance (Dec. 4, 2024); 21 U.S.C. § 360e-4

FDA finalized a framework that lets manufacturers update an AI-enabled medical device after clearance without filing a new submission for each change — but only if they pre-specify what changes are allowed, how they'll be validated, and how transparency to clinicians and patients will be preserved.

Technical detail

Final guidance (Dec. 4, 2024) implementing § 3308 of the Food and Drug Omnibus Reform Act of 2022 (21 U.S.C. § 360e-4). Establishes that a marketing submission for an AI/ML-enabled device software function may include a Predetermined Change Control Plan describing modifications, the Modification Protocol, and an Impact Assessment so that pre-specified changes do not trigger a new 510(k)/De Novo/PMA.

Who is protected: Patients using AI/ML-enabled medical devices that may update after FDA clearance

Who must comply: Sponsors of AI/ML-enabled medical device software functions submitted for FDA marketing authorization

Key facts

JurisdictionUnited States
LevelFederal
StatusIn effect
Protection strengthModerate protection
Effective date2024-12-04
Enacted2024-12-04
CitationFDA Guidance (Dec. 4, 2024); 21 U.S.C. § 360e-4
Enforced byFDA Center for Devices and Radiological Health
Private right of actionNo — agency enforcement only
PenaltiesFailure to follow the PCCP triggers full new-submission requirement; misbranding/adulteration enforcement
Topicshealthcare AI · automated decision-making · AI disclosure and transparency
Last verified2026-06-17
Official sourcePredetermined Change Control Plans for Machine Learning-Enabled Medical Devices — Final Guidance ↗

More AI rules in United States

Related healthcare AI rules elsewhere

See something wrong or out of date? Submit a correction — every entry must carry a verifiable official source.